Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TissuGlu is a single-use, lysine-derived urethane-based surgical adhesive designed for internal use to bond tissue layers together during large flap surgical procedures, such as abdominoplasty. It is applied as a viscous liquid using a hand-held applicator and cures in the presence of moisture from tissue surfaces, forming strong urethane cross-links that hold the tissue planes together. The cured adhesive gradually degrades into absorbable components as natural healing occurs. Its primary mechanism is to eliminate dead space between tissue planes, thereby reducing fluid accumulation and potentially eliminating the need for surgical drains. TissuGlu was developed by Cohera Medical and was the first synthetic internal-use adhesive approved by the FDA[1][2][3][4][5][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TissuGlu.